Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Microfluidic 3D models of cancer.

Sung KE, Beebe DJ.

Adv Drug Deliv Rev. 2014 Dec 15;79-80:68-78. doi: 10.1016/j.addr.2014.07.002. Epub 2014 Jul 10. Review.

2.

Pathophysiologically relevant in vitro tumor models for drug screening.

Das V, Bruzzese F, Konečný P, Iannelli F, Budillon A, Hajdúch M.

Drug Discov Today. 2015 Jul;20(7):848-55. doi: 10.1016/j.drudis.2015.04.004. Epub 2015 Apr 20. Review.

PMID:
25908576
3.

Microfluidic culture models to study the hydrodynamics of tumor progression and therapeutic response.

Buchanan C, Rylander MN.

Biotechnol Bioeng. 2013 Aug;110(8):2063-72. doi: 10.1002/bit.24944. Epub 2013 Jun 15. Review.

PMID:
23616255
4.

Miniaturized pre-clinical cancer models as research and diagnostic tools.

Håkanson M, Cukierman E, Charnley M.

Adv Drug Deliv Rev. 2014 Apr;69-70:52-66. doi: 10.1016/j.addr.2013.11.010. Epub 2013 Dec 1. Review.

5.

Lessons from patient-derived xenografts for better in vitro modeling of human cancer.

Choi SY, Lin D, Gout PW, Collins CC, Xu Y, Wang Y.

Adv Drug Deliv Rev. 2014 Dec 15;79-80:222-37. doi: 10.1016/j.addr.2014.09.009. Epub 2014 Oct 13. Review.

6.

Modeling human carcinomas: physiologically relevant 3D models to improve anti-cancer drug development.

Unger C, Kramer N, Walzl A, Scherzer M, Hengstschläger M, Dolznig H.

Adv Drug Deliv Rev. 2014 Dec 15;79-80:50-67. doi: 10.1016/j.addr.2014.10.015. Epub 2014 Oct 23. Review.

PMID:
25453261
7.

Tissue-engineered models of human tumors for cancer research.

Villasante A, Vunjak-Novakovic G.

Expert Opin Drug Discov. 2015 Mar;10(3):257-68. doi: 10.1517/17460441.2015.1009442. Epub 2015 Feb 7. Review.

8.

Three-dimensional in vitro tumor models for cancer research and drug evaluation.

Xu X, Farach-Carson MC, Jia X.

Biotechnol Adv. 2014 Nov 15;32(7):1256-68. doi: 10.1016/j.biotechadv.2014.07.009. Epub 2014 Aug 10. Review.

9.

The multicellular tumor spheroid model for high-throughput cancer drug discovery.

LaBarbera DV, Reid BG, Yoo BH.

Expert Opin Drug Discov. 2012 Sep;7(9):819-30. doi: 10.1517/17460441.2012.708334. Epub 2012 Jul 12. Review.

PMID:
22788761
10.

3D cell culture systems modeling tumor growth determinants in cancer target discovery.

Thoma CR, Zimmermann M, Agarkova I, Kelm JM, Krek W.

Adv Drug Deliv Rev. 2014 Apr;69-70:29-41. doi: 10.1016/j.addr.2014.03.001. Epub 2014 Mar 15. Review.

PMID:
24636868
11.

Validating antimetastatic effects of natural products in an engineered microfluidic platform mimicking tumor microenvironment.

Niu Y, Bai J, Kamm RD, Wang Y, Wang C.

Mol Pharm. 2014 Jul 7;11(7):2022-9. doi: 10.1021/mp500054h. Epub 2014 Feb 24.

12.

Micro- and nanofluidic systems for high-throughput biological screening.

Hong J, Edel JB, deMello AJ.

Drug Discov Today. 2009 Feb;14(3-4):134-46. doi: 10.1016/j.drudis.2008.10.001. Epub 2008 Dec 4. Review.

PMID:
18983933
13.

Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery.

Ruggeri BA, Camp F, Miknyoczki S.

Biochem Pharmacol. 2014 Jan 1;87(1):150-61. doi: 10.1016/j.bcp.2013.06.020. Epub 2013 Jun 28. Review.

PMID:
23817077
14.

Tumors on chips: oncology meets microfluidics.

Wlodkowic D, Cooper JM.

Curr Opin Chem Biol. 2010 Oct;14(5):556-67. doi: 10.1016/j.cbpa.2010.08.016. Epub 2010 Sep 9. Review.

PMID:
20832352
15.

Three dimensional microfluidic cell arrays for ex vivo drug screening with mimicked vascular flow.

Dereli-Korkut Z, Akaydin HD, Ahmed AH, Jiang X, Wang S.

Anal Chem. 2014 Mar 18;86(6):2997-3004. doi: 10.1021/ac403899j. Epub 2014 Mar 7.

16.

A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro.

Lee JM, Mhawech-Fauceglia P, Lee N, Parsanian LC, Lin YG, Gayther SA, Lawrenson K.

Lab Invest. 2013 May;93(5):528-42. doi: 10.1038/labinvest.2013.41. Epub 2013 Mar 4.

17.

Preclinical models for pediatric solid tumor drug discovery: current trends, challenges and the scopes for improvement.

Kumar S, Mokhtari RB, Yeger H, Baruchel S.

Expert Opin Drug Discov. 2012 Nov;7(11):1093-106. doi: 10.1517/17460441.2012.722077. Epub 2012 Sep 24. Review.

PMID:
22998522
18.

Engineered microenvironments provide new insights into ovarian and prostate cancer progression and drug responses.

Loessner D, Holzapfel BM, Clements JA.

Adv Drug Deliv Rev. 2014 Dec 15;79-80:193-213. doi: 10.1016/j.addr.2014.06.001. Epub 2014 Jun 23. Review.

PMID:
24969478
19.

Cells, tissues, and organs on chips: challenges and opportunities for the cancer tumor microenvironment.

Young EW.

Integr Biol (Camb). 2013 Sep;5(9):1096-109. doi: 10.1039/c3ib40076j. Review.

PMID:
23799587
20.

Challenges in pre-clinical testing of anti-cancer drugs in cell culture and in animal models.

HogenEsch H, Nikitin AY.

J Control Release. 2012 Dec 10;164(2):183-6. doi: 10.1016/j.jconrel.2012.02.031. Epub 2012 Mar 14. Review.

Items per page

Supplemental Content

Write to the Help Desk